Tempest Therapeutics, Inc. Earnings Per Share Disclosure
11. NET LOSS PER SHARE
The following table sets forth the computation of the Company’s basic and diluted net loss per share for the years ended December 31, 2024 and 2023 (in thousands, except share and per share amounts):
|
|
2024 |
|
|
2023 |
|
||
Numerator: |
|
|
|
|
|
|
||
Net loss |
|
$ |
(41,843 |
) |
|
$ |
(29,491 |
) |
Denominator: |
|
|
|
|
|
|
||
Weighted-average common shares outstanding |
|
|
27,901,739 |
|
|
|
15,416,203 |
|
Weighted-average shares used in computing basic and diluted net loss per share |
|
|
27,901,739 |
|
|
|
15,416,203 |
|
|
|
|
|
|
|
|
||
Net loss per share attributable to common stockholders—basic and diluted |
|
$ |
(1.50 |
) |
|
$ |
(1.91 |
) |
As of December 31, 2024 and 2023, the Company’s potentially dilutive securities included unvested stock warrants and stock options, which have been excluded from the computation of diluted net loss per share attributable to common stockholders as the effect would be anti-dilutive. The issuance of pre-funded warrants and vested RSUs have been included in the computation of basic and diluted net loss per share attributable to common stockholders. Based on the amounts outstanding as of December 31, 2024 and 2023, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:
|
|
2024 |
|
|
2023 |
|
||
Options to purchase common stock |
|
|
4,161,162 |
|
|
|
3,554,112 |
|
Restricted stock units |
|
|
— |
|
|
|
125,000 |
|
Common stock warrants |
|
|
6,036 |
|
|
|
6,036 |
|
|
|
|
4,167,198 |
|
|
|
3,685,148 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 27, 2025 | Showing above |
| 2021 | Mar 29, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.